SAB Biotherapeutics
SABS
SABS
25 hedge funds and large institutions have $3.38M invested in SAB Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
25
Holders Change
-1
Holders Change %
-3.85%
% of All Funds
0.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Citadel Advisors
Miami,
Florida
|
+$29.9K |
| 2 |
Creative Planning
Overland Park,
Kansas
|
+$20.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$18.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.51K |
| 5 |
Renaissance Technologies
New York
|
+$1.76K |
Top Sellers
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
-$358K |
| 2 |
SOS
Silver Oak Securities
Jackson,
Tennessee
|
-$29.9K |
| 3 |
BlackRock
New York
|
-$26.8K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$22.3K |
| 5 |
Millennium Management
New York
|
-$22.1K |
